PharmaCyte Biotech Announces IND Submitted to U.S. FDA for Clinical Trial in Locally Advanced, Inoperable Pancreatic Cancer

LAGUNA HILLS, Calif.–(BUSINESS WIRE)– #INDstatus–PharmaCyte Biotech announces its IND submission to the FDA for its clinical trial in locally advanced, inoperable pancreatic cancer.